CLINICAL TRIALS PROFILE FOR JAKAFI
✉ Email this page to a colleague
All Clinical Trials for jakafi
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01251965 ↗ | Phase l/II Study of Ruxolitinib for Acute Leukemia | Terminated | Incyte Corporation | Phase 1/Phase 2 | 2010-12-01 | The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied. |
| NCT01251965 ↗ | Phase l/II Study of Ruxolitinib for Acute Leukemia | Terminated | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 2010-12-01 | The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied. |
| NCT01431209 ↗ | Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Completed | Incyte Corporation | Phase 2 | 2011-08-01 | This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| NCT01431209 ↗ | Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Completed | National Cancer Institute (NCI) | Phase 2 | 2011-08-01 | This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for jakafi
Condition Name
Clinical Trial Locations for jakafi
Trials by Country
Clinical Trial Progress for jakafi
Clinical Trial Phase
Clinical Trial Sponsors for jakafi
Sponsor Name
